Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 7:30 AM EDTPositive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers
Provides Update to Certain Trials based on Expanding Clinical Experience
Conference Call Scheduled for today at 8:30 a.m. ET
NEWTON, Mass., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
"Important data describing the clinical benefit of selinexor across multiple solid and hematologic malignancies was... More
